Patents Assigned to AlphaBeta AB
-
Patent number: 10023610Abstract: The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-? peptide associated with Alzheimer's disease for prevention of aggregation, neurotoxicity and use thereof as drugs for treatment of Alzheimer's disease.Type: GrantFiled: January 16, 2015Date of Patent: July 17, 2018Assignee: AlphaBeta ABInventors: Roger Strömberg, Dmytro Honcharenko, Jyotirmoy Maity, Alok Juneja, Firoz Roshan Kurudenkandy, Jenny Presto, Lisa Dolfe, André Fisahn, Jan Johansson, Lennart Nilsson
-
Patent number: 9580460Abstract: The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the ?-helix of a discordant helix-containing polypeptide. Compounds discovered using these methods are useful for treating or preventing disorders in which amyloid is produced. Such disorders include Alzheimer's disease and prion-associated disorders.Type: GrantFiled: November 8, 2013Date of Patent: February 28, 2017Assignee: AlphaBeta ABInventor: Jan Johansson
-
Patent number: 9522170Abstract: A method involves screening a candidate compound for activity in the treatment of a condition associated with formation of amyloid protein fibrils in a mammal, such as Alzheimer's disease. It is determined whether the trimer/monomer ratio of a chaperone protein is decreased in the presence of the candidate compound. The chaperone protein is or has a high identity to the Brichos domains of Bri2, Bri3 or proSP-C from human. Monomers of the chaperone proteins and/or compounds that promote formation of these monomers are useful for medical treatment of the condition.Type: GrantFiled: March 30, 2012Date of Patent: December 20, 2016Assignee: ALPHABETA ABInventors: Jan Johansson, Jenny Presto
-
Publication number: 20140288005Abstract: An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.Type: ApplicationFiled: May 27, 2014Publication date: September 25, 2014Applicant: Alphabeta ABInventor: Jan Johansson
-
Publication number: 20140243272Abstract: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.Type: ApplicationFiled: May 16, 2014Publication date: August 28, 2014Applicant: ALPHABETA ABInventor: Jan Johansson
-
Patent number: 8785391Abstract: An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.Type: GrantFiled: June 24, 2010Date of Patent: July 22, 2014Assignee: Alphabeta ABInventor: Jan Johansson
-
Patent number: 8785390Abstract: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.Type: GrantFiled: January 29, 2010Date of Patent: July 22, 2014Assignee: Alphabeta ABInventor: Jan Johansson
-
Publication number: 20140187747Abstract: The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the ?-helix of a discordant helix-containing polypeptide. Compounds discovered using these methods are useful for treating or preventing disorders in which amyloid is produced. Such disorders include Alzheimer's disease and prion-associated disorders.Type: ApplicationFiled: November 8, 2013Publication date: July 3, 2014Applicant: ALPHABETA ABInventor: Jan JOHANSSON
-
Publication number: 20140030274Abstract: A method involves screening a candidate compound for activity in the treatment of a condition associated with formation of amyloid protein fibrils in a mammal, such as Alzheimer's disease. It is determined whether the trimer/monomer ratio of a chaperone protein is decreased in the presence of the candidate compound. The chaperone protein is or has a high identity to the Brichos domains of Bri2, Bri3 or proSP-C from human. Monomers of the chaperone proteins and/or compounds that promote formation of these monomers are useful for medical treatment of the condition.Type: ApplicationFiled: March 30, 2012Publication date: January 30, 2014Applicant: AlphaBeta ABInventors: Jan Johansson, Jenny Presto
-
Publication number: 20130172262Abstract: An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.Type: ApplicationFiled: June 24, 2010Publication date: July 4, 2013Applicant: ALPHABETA ABInventor: Jan Johansson
-
Publication number: 20120122794Abstract: An isolated protein selected from the group consisting of (i) proteins comprising an amino acid sequence having at least 70% identity to the C-terminal domain of lung surfactant protein C precursor (CTproSP-C, “CTC”) from a mammal; and (ii) proteins comprising an amino acid sequence having at least 70% identity to the Brichos domain of CTproSP-C from a mammal, is disclosed for treatment of Alzheimer's disease in a mammal, including man.Type: ApplicationFiled: January 29, 2010Publication date: May 17, 2012Applicant: ALPHABETA ABInventor: Jan Johansson
-
Patent number: 6716589Abstract: The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the &agr;-helix of a discordant helix-containing polypeptide. Compounds discovered using these methods are useful for treating or preventing disorders in which amyloid is produced. Such disorders include Alzheimer's disease and prion-associated disorders.Type: GrantFiled: November 19, 2001Date of Patent: April 6, 2004Assignee: AlphaBeta ABInventor: Jan Johansson